Blood Proteins Show Promise as Monitors for Alzheimer Treatment Response

A straightforward blood test could one day provide doctors and patients with an indication of whether an Alzheimer’s therapy is having an effect. A recent investigation at Washington University School of Medicine in St. Louis located dozens of blood plasma proteins that can be visibly affected during the administration of the anti-amyloid treatment lecanemab, marketed as Leqembi. The results, published…

BIG STORY